2024
Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy
Ren J, Liao X, Lewis J, Chang J, Qu R, Carlson K, Foss F, Girardi M. Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy. Nature Communications 2024, 15: 519. PMID: 38225288, PMCID: PMC10789731, DOI: 10.1038/s41467-024-44786-2.Peer-Reviewed Original ResearchMeSH KeywordsClone CellsHumansImmunotherapy, AdoptiveJurkat CellsReceptors, Antigen, T-CellReceptors, Chimeric AntigenConceptsAntibody-dependent cellular cytotoxicityDonor T cellsT cellsAdeno-associated virus transductionHealthy donor T cellsHost-versus-graft reactivityEnhanced antibody-dependent cellular cytotoxicityCAR-T cellsGraft-versus-hostT cell killingT-cell malignanciesMalignant T cellsNormal T-cellT cell receptorOff-target toxicityPre-existing immunoreactivityCAR-TDisease relapseCellular cytotoxicityVirus transductionCurrent treatmentPersister killingFc engineeringB2MIn vivo
2006
Transimmunization for cutaneous T cell lymphoma: A phase I study
Girardi M, Berger CL, Wilson LD, Christensen IR, Thompson KR, Glusac EJ, Edelson RL. Transimmunization for cutaneous T cell lymphoma: A phase I study. Leukemia & Lymphoma 2006, 47: 1495-1503. PMID: 16966259, DOI: 10.1080/10428190600581419.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaCTCL patientsCell lymphomaMalignant cellsCD8 T cell poolPhase I clinical studyT cell poolSignificant mean reductionElectron beam therapyInfiltrative lesionsClinical studiesDendritic antigenBlood monocytesTransimmunizationMean reductionTumor loadingPatientsMonoclonal antibodiesMalignant leukocytesMinimal toxicityBeam therapyPhase ICell poolVivo contact
1995
Specific Suppression of Lupus-Like Graft-Versus-Host Disease Using Extracorporeal Photochemical Attenuation of Effector Lymphocytes
Girardi M, Herreid P, Tigelaar R. Specific Suppression of Lupus-Like Graft-Versus-Host Disease Using Extracorporeal Photochemical Attenuation of Effector Lymphocytes. Journal Of Investigative Dermatology 1995, 104: 177-182. PMID: 7829872, DOI: 10.1111/1523-1747.ep12612741.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, AntinuclearAscitesAutoimmune DiseasesDisease Models, AnimalFemaleGlomerulonephritisGraft vs Host DiseaseGraft vs Host ReactionImmunotherapy, AdoptiveKidneyLupus Erythematosus, SystemicMiceMice, Inbred C3HMice, Inbred C57BLMice, Inbred DBAPUVA TherapyT-LymphocytesVaccinationConceptsSystemic lupus erythematosus-like diseaseB6D2F1 recipientsDisease initiationD2 cellsAntinuclear antibody titerLupus-like graftProgression of graftVersus Host DiseaseSystemic lupus erythematosusC3H/HeJ xDBA/2 splenocytesHost diseaseLupus erythematosusEffector lymphocytesClinical manifestationsClinical parametersHistologic evidenceAntibody titersKidney diseaseAscites formationB6D2F1 miceInterleukin-2T cellsC57BL/6 xComplex antigens